Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/28758 http://dx.doi.org/10.1128/JCM.44.3.1101-1104.2006 |
Resumo: | One hundred recent clinical Pseudomonas aeruginosa isolates were used to assess the quantitative (MIC) and qualitative (susceptibility category) accuracies of the MicroScan WalkAway, VITEK, and VITEK 2 automated susceptibility test systems when five-broad spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested. Isolates were selected so that the MICs for the isolates over-represented the MICs near the breakpoints to assess precisely the agreement between the results obtained with the automated systems and the results obtained by the reference tests. the categorical and MIC results from the automated systems were compared to the consensus result of three reference methods: broth microdilution, agar dilution, and disk diffusion. the consensus categorical testing (susceptibility and resistance) rates were 47 and 27%, respectively, for aztreonam; 59 and 14%, respectively, for cefepime; 44 and 43%, respectively, for ceftazidime; 71 and 19%, respectively, for imipenem; and 50 and 50%, respectively, for piperacillin-tazobactam. All systems tested exhibited a high, unacceptable level of very major (false-susceptible) errors for piperacillin-tazobactam (19 to 27%). Major (false-resistant) error rates were generally acceptable (0 to 3%), but minor error rates were elevated (8 to 32%) for cefepime (VITEK 2 and VITEK) and for aztreonam (all three systems), leading to consistent trends toward false resistance. Manufacturer reevaluation of these automated systems for the testing of selected beta-lactams with current clinical isolates of P. aeruginosa that exhibit contemporary resistance mechanisms would be prudent to minimize the potential for serious reporting errors. |
id |
UFSP_3011d0449a7f9379fc6c038c6efff66e |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/28758 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Sader, Helio S. [UNIFESP]Fritsche, Thomas R.Jones, Ronald N.JMI Labs IncUniversidade Federal de São Paulo (UNIFESP)Tufts Univ2016-01-24T12:41:00Z2016-01-24T12:41:00Z2006-03-01Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 44, n. 3, p. 1101-1104, 2006.0095-1137http://repositorio.unifesp.br/handle/11600/28758http://dx.doi.org/10.1128/JCM.44.3.1101-1104.2006WOS000236095000066.pdf10.1128/JCM.44.3.1101-1104.2006WOS:000236095000066One hundred recent clinical Pseudomonas aeruginosa isolates were used to assess the quantitative (MIC) and qualitative (susceptibility category) accuracies of the MicroScan WalkAway, VITEK, and VITEK 2 automated susceptibility test systems when five-broad spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested. Isolates were selected so that the MICs for the isolates over-represented the MICs near the breakpoints to assess precisely the agreement between the results obtained with the automated systems and the results obtained by the reference tests. the categorical and MIC results from the automated systems were compared to the consensus result of three reference methods: broth microdilution, agar dilution, and disk diffusion. the consensus categorical testing (susceptibility and resistance) rates were 47 and 27%, respectively, for aztreonam; 59 and 14%, respectively, for cefepime; 44 and 43%, respectively, for ceftazidime; 71 and 19%, respectively, for imipenem; and 50 and 50%, respectively, for piperacillin-tazobactam. All systems tested exhibited a high, unacceptable level of very major (false-susceptible) errors for piperacillin-tazobactam (19 to 27%). Major (false-resistant) error rates were generally acceptable (0 to 3%), but minor error rates were elevated (8 to 32%) for cefepime (VITEK 2 and VITEK) and for aztreonam (all three systems), leading to consistent trends toward false resistance. Manufacturer reevaluation of these automated systems for the testing of selected beta-lactams with current clinical isolates of P. aeruginosa that exhibit contemporary resistance mechanisms would be prudent to minimize the potential for serious reporting errors.JMI Labs Inc, N Liberty, IA 52317 USAUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, BrazilTufts Univ, Sch Med, Boston, MA 02111 USAUniversidade Federal de São Paulo, Div Infect Dis, São Paulo, BrazilWeb of Science1101-1104engAmer Soc MicrobiologyJournal of Clinical MicrobiologyAccuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agentsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000236095000066.pdfapplication/pdf55672${dspace.ui.url}/bitstream/11600/28758/1/WOS000236095000066.pdfe65b49adc9904c8afb93da409e3a5f4fMD51open accessTEXTWOS000236095000066.pdf.txtWOS000236095000066.pdf.txtExtracted texttext/plain24831${dspace.ui.url}/bitstream/11600/28758/2/WOS000236095000066.pdf.txtb91ad9b34ff50ade356133827e65b22fMD52open access11600/287582023-01-12 21:39:40.668open accessoai:repositorio.unifesp.br:11600/28758Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-01-13T00:39:40Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents |
title |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents |
spellingShingle |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents Sader, Helio S. [UNIFESP] |
title_short |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents |
title_full |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents |
title_fullStr |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents |
title_full_unstemmed |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents |
title_sort |
Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents |
author |
Sader, Helio S. [UNIFESP] |
author_facet |
Sader, Helio S. [UNIFESP] Fritsche, Thomas R. Jones, Ronald N. |
author_role |
author |
author2 |
Fritsche, Thomas R. Jones, Ronald N. |
author2_role |
author author |
dc.contributor.institution.none.fl_str_mv |
JMI Labs Inc Universidade Federal de São Paulo (UNIFESP) Tufts Univ |
dc.contributor.author.fl_str_mv |
Sader, Helio S. [UNIFESP] Fritsche, Thomas R. Jones, Ronald N. |
description |
One hundred recent clinical Pseudomonas aeruginosa isolates were used to assess the quantitative (MIC) and qualitative (susceptibility category) accuracies of the MicroScan WalkAway, VITEK, and VITEK 2 automated susceptibility test systems when five-broad spectrum beta-lactams, aztreonam, cefepime, ceftazidime, imipenem, and piperacillin-tazobactam, were tested. Isolates were selected so that the MICs for the isolates over-represented the MICs near the breakpoints to assess precisely the agreement between the results obtained with the automated systems and the results obtained by the reference tests. the categorical and MIC results from the automated systems were compared to the consensus result of three reference methods: broth microdilution, agar dilution, and disk diffusion. the consensus categorical testing (susceptibility and resistance) rates were 47 and 27%, respectively, for aztreonam; 59 and 14%, respectively, for cefepime; 44 and 43%, respectively, for ceftazidime; 71 and 19%, respectively, for imipenem; and 50 and 50%, respectively, for piperacillin-tazobactam. All systems tested exhibited a high, unacceptable level of very major (false-susceptible) errors for piperacillin-tazobactam (19 to 27%). Major (false-resistant) error rates were generally acceptable (0 to 3%), but minor error rates were elevated (8 to 32%) for cefepime (VITEK 2 and VITEK) and for aztreonam (all three systems), leading to consistent trends toward false resistance. Manufacturer reevaluation of these automated systems for the testing of selected beta-lactams with current clinical isolates of P. aeruginosa that exhibit contemporary resistance mechanisms would be prudent to minimize the potential for serious reporting errors. |
publishDate |
2006 |
dc.date.issued.fl_str_mv |
2006-03-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T12:41:00Z |
dc.date.available.fl_str_mv |
2016-01-24T12:41:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 44, n. 3, p. 1101-1104, 2006. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/28758 http://dx.doi.org/10.1128/JCM.44.3.1101-1104.2006 |
dc.identifier.issn.none.fl_str_mv |
0095-1137 |
dc.identifier.file.none.fl_str_mv |
WOS000236095000066.pdf |
dc.identifier.doi.none.fl_str_mv |
10.1128/JCM.44.3.1101-1104.2006 |
dc.identifier.wos.none.fl_str_mv |
WOS:000236095000066 |
identifier_str_mv |
Journal of Clinical Microbiology. Washington: Amer Soc Microbiology, v. 44, n. 3, p. 1101-1104, 2006. 0095-1137 WOS000236095000066.pdf 10.1128/JCM.44.3.1101-1104.2006 WOS:000236095000066 |
url |
http://repositorio.unifesp.br/handle/11600/28758 http://dx.doi.org/10.1128/JCM.44.3.1101-1104.2006 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Journal of Clinical Microbiology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
1101-1104 |
dc.publisher.none.fl_str_mv |
Amer Soc Microbiology |
publisher.none.fl_str_mv |
Amer Soc Microbiology |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/28758/1/WOS000236095000066.pdf ${dspace.ui.url}/bitstream/11600/28758/2/WOS000236095000066.pdf.txt |
bitstream.checksum.fl_str_mv |
e65b49adc9904c8afb93da409e3a5f4f b91ad9b34ff50ade356133827e65b22f |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1802764113521147904 |